ES2559294T3 - Bencenopropanamida y bencenopropenamida N-sustituidas para uso en la prevención o el tratamiento de trastornos afectivos - Google Patents

Bencenopropanamida y bencenopropenamida N-sustituidas para uso en la prevención o el tratamiento de trastornos afectivos Download PDF

Info

Publication number
ES2559294T3
ES2559294T3 ES12780536.4T ES12780536T ES2559294T3 ES 2559294 T3 ES2559294 T3 ES 2559294T3 ES 12780536 T ES12780536 T ES 12780536T ES 2559294 T3 ES2559294 T3 ES 2559294T3
Authority
ES
Spain
Prior art keywords
compound
compounds
weight
treatment
benzenepropenamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12780536.4T
Other languages
English (en)
Spanish (es)
Inventor
Eliahu Kaplan
Irit Gil-Ad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaremed Ltd
Original Assignee
Novaremed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaremed Ltd filed Critical Novaremed Ltd
Application granted granted Critical
Publication of ES2559294T3 publication Critical patent/ES2559294T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES12780536.4T 2011-09-21 2012-09-10 Bencenopropanamida y bencenopropenamida N-sustituidas para uso en la prevención o el tratamiento de trastornos afectivos Active ES2559294T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1116335.9A GB201116335D0 (en) 2011-09-21 2011-09-21 A method of treating or preventing affective disorders
GB201116335 2011-09-21
PCT/IB2012/054700 WO2013042005A1 (en) 2011-09-21 2012-09-10 N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders

Publications (1)

Publication Number Publication Date
ES2559294T3 true ES2559294T3 (es) 2016-02-11

Family

ID=44937647

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12780536.4T Active ES2559294T3 (es) 2011-09-21 2012-09-10 Bencenopropanamida y bencenopropenamida N-sustituidas para uso en la prevención o el tratamiento de trastornos afectivos

Country Status (11)

Country Link
US (1) US9133103B2 (enExample)
EP (1) EP2758046B1 (enExample)
JP (1) JP6067022B2 (enExample)
CN (1) CN103826622B (enExample)
AU (1) AU2012311183B2 (enExample)
CA (1) CA2849055C (enExample)
DK (1) DK2758046T3 (enExample)
ES (1) ES2559294T3 (enExample)
GB (1) GB201116335D0 (enExample)
IL (1) IL231609A (enExample)
WO (1) WO2013042005A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015173813A1 (en) * 2014-05-14 2015-11-19 Novaremed Ltd. Pharmaceutical composition comprising stereoisomers of n-(1-(4-hydroxyphenyl)-3-(2-hydroxypropoxy)propan-2-yl)-3-phenylpropanamide for the prevention and treatment of type ii diabetes
CN107011313B (zh) 2016-01-27 2021-11-30 天士力医药集团股份有限公司 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用
EP3939578A1 (en) * 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2535975T3 (es) * 2002-10-03 2015-05-19 Novaremed Ltd. Compuestos para su uso en el tratamiento de enfermedades autoinmunitarias, enfermedades inmunoalérgicas y rechazo de trasplantes de órganos o tejidos
US7674829B2 (en) * 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases
MXPA06013162A (es) * 2004-05-12 2007-02-13 Pfizer Prod Inc Derivados de piperidina como antagonistas de neurocinina 1 y neurocinina 3.
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
PL2475361T3 (pl) * 2009-09-09 2020-07-13 Novaremed Ltd. N-podstawione benzenopropanoamidy do stosowania w leczeniu bólu i stanu zapalnego

Also Published As

Publication number Publication date
HK1200353A1 (zh) 2015-08-07
CN103826622A (zh) 2014-05-28
JP2014530200A (ja) 2014-11-17
CA2849055C (en) 2019-11-26
CA2849055A1 (en) 2013-03-28
US9133103B2 (en) 2015-09-15
JP6067022B2 (ja) 2017-01-25
EP2758046B1 (en) 2015-10-21
EP2758046A1 (en) 2014-07-30
AU2012311183B2 (en) 2016-09-22
WO2013042005A1 (en) 2013-03-28
IL231609A0 (en) 2014-05-28
CN103826622B (zh) 2016-06-08
DK2758046T3 (da) 2016-02-01
GB201116335D0 (en) 2011-11-02
US20140275273A1 (en) 2014-09-18
AU2012311183A1 (en) 2014-04-03
IL231609A (en) 2016-11-30

Similar Documents

Publication Publication Date Title
JP7050751B2 (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
TW201120040A (en) Bruton's tyrosine kinase inhibitors
TW201036988A (en) Phosphothiophene and phosphothiazole HCV polymerase inhibitors
CN103289075A (zh) 聚乙二醇与纳洛酮的结合物及其药物组合物和应用
WO2021022076A1 (en) Molecules and methods related to treatment of uncontrolled cellular proliferation
ES2559294T3 (es) Bencenopropanamida y bencenopropenamida N-sustituidas para uso en la prevención o el tratamiento de trastornos afectivos
US20110178104A1 (en) Anti-Heparin Compounds
ES2459742T3 (es) Compuesto tricíclico y uso del mismo
CA3048546A1 (en) Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
TW201041852A (en) 2,5-disubstituted arylsulfonamide CCR3 antagonists
EP3368023B1 (en) Derivatives of porphyrins, their process of preparation and their use for treating viral infections
TW200835693A (en) Preparation and utility of non-nucleoside reverse transcriptase inhibitors
Tomasi et al. Targeting the polyamine transport system with benzazepine-and azepine-polyamine conjugates
CN112047944A (zh) 一种选择性抑制激酶化合物及其用途
EP3126356A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
CN104211682B (zh) 吡啶类化合物及其用途
TW200900408A (en) Fused pyridine derivative
CN104744451A (zh) 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
CN116139148A (zh) 药物组合的医药用途
CN110092750B (zh) 五氟硫烷基取代的酰胺类化合物、其制备方法及其在医药学上的应用
CN113831346B (zh) 多靶点抗肿瘤小分子及其衍生物、制法、药物组合物和应用
HK1200353B (en) N-substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders
Colabufo New tetrahydroisoquinoline based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligands.
CN116253704A (zh) Paeoveitol D衍生物及其药物组合物和其制备方法与其应用
ES2641948T3 (es) Derivados de benzo[e][1,3]oxazin-4-ona como inhibidores de fosfoinositida-3-quinasa